Business Information
The group's principal activities are manufacturing and marketing health care products. It is divided into four distinctive units; diabetes care, coagulation disorders, human growth hormone and hormone replacement therapy. The diabetes care brand names include novo-rapid, innolet, innoco and novonorm. Brand name for treating coagulation disorders is novoseven. Growth hormones include norditropin simplexx. Hormone replacement products are novofem, activelle, kliogest, trisequens, estrofem and vagifem.
|
|
Name |
Title
|
Email
|
| Goran Ando | Vice Chmn. | N/A | | Sten Scheibye | Chmn. | N/A | | Lars Sorensen | CEO, Pres. | N/A | | Mads Lausten | Head - Investor Relations | Available | | Jesper Brandgaard | CFO, Exec. VP | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 6,857,511 | 1,116,870 | | 2005 | 5,350,960 | 776,333 | | 2004 | 5,324,285 | 859,229
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
